Power Law company profile

Ensoma

Biotech & Life Sciences · Boston, United States · Founded 2019

Ensoma operates in the biotechnology sector, focusing on developing advanced in vivo treatments that utilize DNA editing to engineer immune cells for curative therapies. The company serves healthcare providers and patients, particularly those suffering from diseases that can be treated through genetic engineering of the hematopoietic system. Ensoma's business model revolves around leveraging its proprietary technology platform, Engenious, which combines innovative delivery mechanisms with a comprehensive DNA editing toolkit. This allows for precise engineering of immune cells, offering a one-time treatment solution that aims to cure diseases from within the body. Ensoma generates revenue through partnerships with healthcare institutions and top-tier investors who support its bold vision of pioneering a new kind of medicine. The company operates primarily in the United States but has a global outlook, aiming to transform the landscape of curative therapies through its cutting-edge technology. Keywords: DNA editing, in vivo treatments, immune cells, curative therapies, hematopoietic system, biotechnology, healthcare, genetic engineering, Engenious platform, top-tier investors.

Valuation

$100–500M

Latest valuation · 2025

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Total funding● Pre-IPO

$100–500M

Unlock exact value

Investors

25 investors on Ensoma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 21 investors entered at this stage

5AM Ventures

Takeda Ventures

F-Prime

Alexandria Venture Investments

Cormorant Capital

Hans-Peter Kiem

RIT Capital Partners

Viking Global Investors

SymBiosis

André Lieber

Arix Bioscience

Bill & Melinda Gates Foundation

Cormorant Asset Management

Fred Hutchinson Cancer Research Center

Qatar Investment Authority

Solasta Ventures

Catalio Capital Management

Mirae Asset

Bioluminescence Ventures

Kite Pharma

Delos Capital

Series B+ 4 investors entered at this stage

Gilead Sciences

Hanwha

Mirae Asset Capital

RTW Investments

Global footprint

Where Ensoma has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States95.2%

🇬🇧 United Kingdom1.6%

🇩🇰 Denmark1.6%

🇦🇺 Australia1.6%

4 countries shown

Talent graph

The shape of Ensoma's talent

Dealroom maps Ensoma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

12 team members profilednamed & role-tagged by Dealroom

53 employeestotal headcount

7 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Ensoma's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Ensoma

An AI-synthesized read of the highest-engagement posts about Ensoma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ensoma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles